

Amendments to the Claims:

Claim 1 (canceled)

Claim 2 (currently amended) ~~Use according to~~ The method of claim 18 wherein mastitis is chronic mastitis.

Claim 3 (currently amended) ~~Use according to~~ The method of claim 18 wherein mastitis is acute mastitis.

Claim 4 (canceled)

Claim 5 (currently amended) ~~Use according to any one of the preceding claims~~ The method of claim 8 wherein the NF- κ B inhibitor is a specific NF- κ B inhibitor .

Claim 6 (currently amended) ~~Use according to any one of the preceding claims~~ The method of claim 8 wherein the NF- κ B inhibitor is selected from 15d-PGJ2, tepoxalin, cycloepoxydon, (+)-cycloepoxydon, (-)-cyclo-epoxydon , sodium diethyldithiocarbamate, gliotoxin, MG-132, BAY 11-7082, BAY 11-7085 or bortezomib.

Claim 7 (currently amended) ~~Use according to any one of the preceding claims~~ The method of claim 8 wherein the NF- κ B inhibitor is administered intramammary.

Claim 8 (new) A method for the treatment of mastitis comprising administering to a subject in need thereof an effective amount of a NF- κ B inhibitor.

Claim 9 (new) A method for the treatment of mastitis comprising administering to a subject in need thereof an effective amount of a NF- κ B inhibitor in combination with an antibiotic.

Claim 10 (new) The method of claim 2, wherein the NF- κ B inhibitor is selected from 15d-PGJ2, tepoxalin, cycloepoxydon, (+)-cycloepoxydon, (-)-cyclo-epoxydon , sodium diethyldithiocarbamate, gliotoxin, MG-132, BAY 11-7082, BAY 11-7085 or bortezomib.

Claim 11 (new) The method of claim 3, wherein the NF- κ B inhibitor is selected from 15d-PGJ2, tepoxalin, cycloepoxydon, (+)-cycloepoxydon, (-)-cyclo-epoxydon , sodium diethyldithiocarbamate, gliotoxin, MG-132, BAY 11-7082, BAY 11-7085 or bortezomib.